It's great that the company derives revenue from it's association with BARDA. But you can't ignore that that revenue would not even exist if not for the reimbursement of costs. In FY 18, the company realized $3.827 million from the BARDA contract. At the same time it spent $3.806 million on research and development. Now, it's certain that not the entirety of this expense was BARDA related, but it is likely that the BARDA-related expense was at least $3.4 million in order to justify revenues of the order indicated. Thus, it's likely that the BARDA-related net revenue was in the order of $200,000, based on a typical fee structure of about 6%.
- Forums
- ASX - By Stock
- Polynovo’s Novosorb is a med-tech Swiss Army Knife
It's great that the company derives revenue from it's...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.06 |
Change
0.000(0.00%) |
Mkt cap ! $1.422B |
Open | High | Low | Value | Volume |
$2.07 | $2.08 | $2.04 | $1.857M | 901.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 11510 | $2.04 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.07 | 76972 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 11510 | 2.040 |
5 | 91305 | 2.030 |
2 | 4000 | 2.020 |
9 | 23969 | 2.010 |
11 | 23430 | 2.000 |
Price($) | Vol. | No. |
---|---|---|
2.070 | 36972 | 8 |
2.080 | 6972 | 2 |
2.090 | 10000 | 1 |
2.100 | 7200 | 1 |
2.110 | 4692 | 1 |
Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |